Biomedical research of the last few decades has been characterized by an overreliance on statistical testing. Researchers like many zeros in their P values to convince their audience on the validity of their claims from empirical observations. The area of predictive modeling has been no exception. When the focus shifted from association, eg, expressed by hazard ratios, to the added predictive ability of new biomarkers, P values remained at the forefront in reporting. A contributing factor is the difficult Figure 1 . Distributions of model performance improvement statistics in 5000 simulations where four uninformative markers are added to a baseline clinical risk score. All assumptions follow Pepe et al. (6) . Event rate 10%. Results based on samples of 420 individuals drawn from a population of 10 000 (as in Pepe et al. [6] ) and samples of 4200 individuals drawn from a population of 100 000 (10 times the sizes of Pepe et al. [6] ). Left panels illustrate distributions on development samples and right panels show distribution based on models derived on development samples and applied to validation data samples. NRI(0.10) indicates category-based NRI with single risk threshold interpretation of the change in magnitude of improvement in the commonly used performance measure in predictive modeling, ie, the area under the curve (AUC). Concurrently, many reports noted that biomarkers of exceptional strength are needed to discernibly increase the AUC and that P values obtained using the popular DeLong's test tend to be conservative (1,2). These problems motivated research on identifying new measures of added predictive ability of biomarkers and led to the introduction of the continuous, category-based and weighted net reclassification indices (NRI) (3).
We note that the majority of applications of NRI measures have also relied on P values for their interpretation. This is unfortunate for two reasons. First, even if correct, P values can only help quantify the probability of a chance finding and tell us nothing about the strength of improvement in the model. Second, recent research has shown that these P values are generally incorrect, at least for nested models, where extensions of models with new markers are evaluated. Statistical research has shown that the distributions of the proposed test statistics are different under the null and alternative hypotheses, making that reliable tests for the difference in AUC do not exist (1, 2) . The recent work of Pepe et al. published in the Journal (4) shows that attaching P values to the continuous NRI is incorrect. Another paper from this group (5) sheds further light on the best statistical practice. The only P value that should be reported is the one based on the likelihood ratio test from the relevant prediction model (1, 5) . We fully support these conclusions.
The recent paper (4) illustrates another problem with the continuous NRI-it appears positively biased for noninformative markers. We offer two comments on this important finding. First, the magnitude of the problem decreases with increasing sample size (Figure 1) . Using the validation sample, the mean continuous NRI is 0.13 with n = 420 and 0.05 with n = 4200. Still, it is essential that those wishing to use continuous NRI follow recently proposed guidelines to avoid spurious claims (6, 7) . Second, the problem of positive bias does not apply to the category-based NRI. As illustrated in Figure 1 , the distribution of the category-based NRI is roughly symmetrical around zero for both development and validation data (all means close to zero). In this regard, it may be attractive over the difference in AUC which appears overoptimistic on the development set. Such improvements in model performance according to category-based NRI or AUC should be accompanied by 95% confidence intervals to indicate uncertainty.
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